Sector News

Concordia Healthcare to buy some assets of Covis Pharma for $1.2 bln

March 10, 2015
Life sciences
(Reuters) – Concordia Healthcare Corp, which makes drugs for rare diseases and devices for diabetic patients, said it would buy some assets of privately held Covis Pharma Holdings SARL for $1.2 billion in cash.
 
Concordia said the drug portfolio it will acquire consists of 18 branded generic products, including generic drugs for heart diseases, neurological disorders and cancer.
  
Covis expects the portfolio to generate revenue of $140 million to $145 million in 2014, with gross margin of about 90 percent, Concordia said.
 
Concordia expects the deal to add over 50 percent to adjusted earnings in 2015.
 
The company reported a profit in the third quarter of 2014 after two quarters of losses. Overall it earned about $7.9 million in the first three quarters of 2014.
 
Oakville, Ontario-based Concordia said the drug portfolio is part of the two Covis units it is acquiring, Covis Pharma SARL and Covis Injectables SARL – both headquartered in Switzerland.
 
Covis Pharma Holdings, the parent company, is controlled by affiliates of Cerberus Capital Management L.P., Princeton Biopharma Capital Partners LLC and Bourne Partners.
 
RBC Capital Markets is Concordia’s financial adviser, and Sullivan & Cromwell LLP and Fasken Martineau DuMoulin LLP is its legal counsel.
 
Lowenstein Sandler LLP is Covis’ legal counsel, and Bourne Partners served its financial adviser. (Reporting by Sneha Banerjee in Bengaluru; Editing by Savio D’Souza)

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.